Commiphora myrra, alternative treatment in migraine prophylaxis: open label prospective pilot study
Many substances extracted from minerals, plants, microorganisms, and animals are defined as nutraceuticals because they have a preventive therapeutic value on health; some of them, such as magnesium, riboflavin, coenzyme Q10, Tanacetum parthenium, Petasites hybridus, gingolide, for their particular biochemical, vascular, and neuroreceptoral mechanisms have been used in the prophylaxis of primary headaches, either alone or in combination products. The European, American, and Canadian therapeutic guidelines have provided the recommendations and evidence for their use in migraine prophylaxis .
Recently, attention has been given to Myrrh, a resin derived from the Commiphora myrra of the Burseraceae family (patented MyrLiq formula), which for the high content of furanodienes, possesses anti-inflammatory, analgesic, and anesthetic properties [2, 3].
Myrrh is proposed in combination with other migraine prevention nutraceuticals, such as Gingko biloba, riboflavin, and coenzyme Q10, already...
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Germano A, Occhipinti A, Barbero F and Maffei ME (2017) A pilot study on bioactive constituents and analgesic effects of MyrLiq, a Commiphora myrra extract with a high furanodiene content. Biomed Res Int Article ID 3804356. https://doi.org/10.1155/2017/3804356